知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

35 records (took 0.017 seconds)

    Pipette tip disposal assembly
    1.
    发明授权
    Pipette tip disposal assembly 有权

    公开(公告)号：US12208397B2

    公开(公告)日：2025-01-28

    申请号：US17265441

    申请日：2019-08-02

    Applicant: RANDOX LABORATORIES LTD

    Inventor： Paul Courtney ,  Martin Reid ,  Stuart Jackson ,  John Lamont ,  Ivan McConnell ,  Peter Fitzgerald

    IPC: B01L9/00 ,  B01L1/00 ,  B25J9/02

    Abstract: There is provided a pipette tip disposal assembly. The assembly comprises a receiving element adapted to support an end of at least one pipette tip, the at least one pipette tip being toppled in use from the receiving element along a first direction; and a container positioned to receive the at least one toppled pipette tip, the at least one pipette tip falling towards a base of the container on being received by the container. The base of the container has a first linear dimension aligned with the first direction corresponding to the length of a pipette tip.

    KIDNEY DISEASE BIOMARKER
    8.
    发明申请
    KIDNEY DISEASE BIOMARKER 审中-公开
    KIDNEY疾病生物标志

    公开(公告)号：US20150219670A1

    公开(公告)日：2015-08-06

    申请号：US14421382

    申请日：2013-08-12

    Applicant: Randox Laboratories Ltd.

    Inventor： Ivan McConnell ,  Stephen Peter Fitzgerald ,  John Lamont ,  Claran Richardson

    IPC: G01N33/68 ,  G01N33/70 ,  G01N33/573

    CPC classification number: G01N33/6893 ,  C07K14/475 ,  C07K14/8139 ,  C12N9/104 ,  G01N33/573 ,  G01N33/6845 ,  G01N33/70 ,  G01N33/92 ,  G01N2333/47 ,  G01N2333/8139 ,  G01N2333/9108 ,  G01N2333/91188 ,  G01N2800/347 ,  G01N2800/50 ,  G01N2800/56

    Abstract: The present invention provides a method of stratifying a patient suffering from CKD into one of stages 1-3 of CKD, comprising determining the level of the biomarkers FABP1, γ-GT, AST, creatinine and cystatin C in a sample obtained from the patient and comparing the level of FABP1 in the sample to a control value and the levels of γ-GT, AST, creatinine and cystatin C in the sample to a range of control values for each biomarker, wherein an increased level of FABP1 compared to the control value and levels of γ-GT, AST, creatinine and cystatin C within the range of control values for each biomarker indicate that the patient suffers from stage 1 CKD or wherein an increased level of FABP1 compared to the control value, levels of γ-GT and AST within the range of control values for each biomarker, and increased levels of creatinine and cystatin C compared to an upper threshold of the control range for these biomarkers indicate that the patient suffers from stage 2 or stage 3 CKD.

    Abstract translation: 本发明提供了将患有CKD的患者分为CKD的1-3期的方法，包括测定从患者获得的样品中生物标志物FABP1，γ-GT，AST，肌酐和半胱氨酸蛋白酶抑制剂C的水平，以及 将样品中FABP1的水平与对照值和样品中的γ-GT，AST，肌酐和半胱氨酸蛋白酶抑制剂C的水平进行比较，对每种生物标志物的对照值范围进行比较，其中FABP1水平与对照值相比增加 并且每个生物标志物的对照值范围内的γ-GT，AST，肌酐和半胱氨酸蛋白酶抑制剂C的水平表明患者患有1期CKD或其中FABP1水平与对照值相比增加，γ-GT水平和 在每个生物标志物的对照值范围内的AST和与这些生物标志物的对照范围的上限阈值相比，肌酐和半胱氨酸蛋白酶抑制剂C的水平升高表明患者患有2期或3期CKD。

    Chemiluminescence detector
    9.
    发明授权
    Chemiluminescence detector 有权

    公开(公告)号：US11169093B2

    公开(公告)日：2021-11-09

    申请号：US16069492

    申请日：2017-01-13

    Applicant: Randox Laboratories Ltd.

    Inventor： Stuart Jackson ,  Ivan McConnell ,  Peter Fitzgerald

    IPC: G01N21/76 ,  G01N21/64

    Abstract: The present invention provides a chemiluminescence detector, which comprises an image capture device sensitive to chemiluminescence located within a container. The container has an array of apertures located in a field of view of the image capture device, and each aperture is defined by a through-bore in a wall of the container. The exterior of the container is engagable with a plurality of sample holders, each sample holder being in alignment with a respective aperture when engaged with the exterior of the container. The passage of light into the container through each aperture is restrictable by a closure device, passage of light into the container through the apertures is thereby controllable.

Patent Agency Ranking